Hematology / Oncology

Brian D. Weiss, MD

Appointment

Assistant Professor of Pediatrics

Email

brian.weiss@cchmc.org

Phone

513-636-9863

Fax

513-636-3549

Credentials

MD: Northwestern University Medical School, Chicago, IL, 1993

Residency and Chief Residency: Pediatrics, University of California, San Francisco, CA, 1993-1997

Fellowship: Pediatric Hematology/Oncology, University of California, San Francisco, CA, 1997-2000

Certification

National Medical Board, 1994
Pediatrics, 1996, 2002
Pediatric Hematology-Onoclogy, 2000, 2007

Awards and Honors

Frank A. Campini Research Fellow
Patriot Award, US Armed Forces
Intern teaching Award
Editor-in-chief, Northwestern University Medical Center Literary Journal

Research

Principal Investigator for:

NF Consortium Study 102: mTOR Inhibitors for NF-Related Plexiform Neurofibromas
ANBL09P1: A COG Pilot Study of Intensive Induction Therapy and 131I-MIBG with Myeloablative Carboplatin, Etoposide and Melphalan (CEM) for Newly Diagnosed High-Risk Neuroblastoma

Vice-Chair for:

N2007-01: A NANT Phase 1 Study of Ultratrace Iobenguane I 131 in Patients with Relapsed / Refractory High-Risk Neuroblastoma

Publications, Most Recent

Connect to Brian Weiss' publications on PubMed

Rayburg M, Towbin A, Yin H, Maugans T, Mauer, B, Nagarajan R, Weiss B. Langerhans cell histiocytosis in a patient with stage 4 neuroblastoma receiving oral fenretinide. In press, Pediatr Blood Cancer.

Weiss B, Geiger H, Davies SM. Possible leukemogenic potential of temozolomide. Pediatr Blood Cancer 52:553, 2009.

Hummel T, Towbin A, Miles L, Durrani A, Perentesis J, and Weiss B. Response Of NF1-Related Plexiform Neurofibroma To High Dose Carboplatin. Abstract: Connective Tissue Oncology Society Proceedings, 2008.

Chan R, Cooper T, Kratz C,Weiss B,Loh M. Juvenile Myelomonocytic Leukemia: A Report from the 2^nd International JMML Symposium. Leuk Res, 2008.

Wagner LM, McLendon RE, Yoon KJ, Weiss B, Billups C, and Danks M: Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma. Clin Cancer Res 13:5418-25, 2007

Geiger H, Schleimer D, Nattamai KJ, Dannenmann S, Davies SM, Weiss B. Mutagenic Potential of Temozolomide in Bone Marrow Cells In Vivo. Blood 107(7): 3010-1, 2006.

Weiss B and Shannon K. Preliminary Examples of Preclinical Trials, in Mouse Models of Cancer, ed. Eric Holland. Wiley-Liss, 2004.

Presentations, Most Recent

Society of Nuclear Medicine, June 2009
NF Consortium, June 2009
Children’s Tumor Foundation-Michigan Chapter, May 2009
Children’s Oncology Group, March 2009
NF Consortium, November 2008
Children’s Oncology Group, October 2008
NF Consortium, June 2008
Children’s Tumor Foundation, June 2008
Children’s Oncology Group, April 2008
CCHMC Neurofibromatosis Conference, March 2008
Grand Rounds: UT Southwestern February 2008
NCI-sponsored mTOR Workshop January 2008
International JMML Symposium, December 2007
NF Consortium, November 2007
Children's Oncology Group, October 2007
Society of Nuclear Medicine, June 2007
NF Consortium, June 2007
Akron Children's Hospital, May 2007
Children's Oncology Group, October 2006
American Society of Hematology, December 2005
Children's Oncology Group, October 2005
St. Elizabeth's Hospital, January 2005

Professional Organization Memberships

American Society of Hematology
American Society of Clinical Oncology
American Society of Pediatric Hematology/Oncology
International JMML Foundation, Medical Advisory Board Member
COG High-Risk Neuroblastoma Task Force
Children's Oncology Group-member

Member, NF Consortium Plexiform Neurofibroma Taks Force
Member, NF Consortium Malignant Peripheral Nerve Sheath Tumor (MPNST) Task Force

Special Interests

Targeted Agents for Neurofibromatosis Type 1-Related Malignancies (including Plexiform Neurofibromas, Malignant Peripheral Nerve Sheath Tumors, Optic Pathway Gliomas, and Juvenile Myelomonocytic Leukemias)
High-risk Neuroblastoma and ¹³¹I-MIBG Treatment for treatment of Neuroblastoma
New Approaches to Targeting and Killing Neuroblastoma Cells